Cannabis clinical trials at UCSF
6 in progress, 2 open to eligible people
N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use
open to eligible people ages 18 years and up
Tobacco and cannabis co-use is a common and growing public health problem, especially in states that have legalized cannabis. There are no pharmacologic treatments for co-occurring tobacco and cannabis use. Co-use may make quitting either substance more difficult, given the synergistic effects of cannabis and nicotine on neurobiological systems that mediate reward and shared cues reinforcing co-use. N-acetylcysteine (NAC), an FDA-approved medication and over-the-counter supplement, has shown promise in animal studies and randomized controlled trials (RCTs) in reducing tobacco and cannabis craving and use.
San Francisco, California
THC Crossover Study
open to eligible people ages 21 years and up
This is a randomized, crossover study enrolling experienced dual cannabis-tobacco smokers (N=18) to describe the differences in THC and toxicant exposure, examining pharmacokinetic, subjective, and cardiovascular effects from smoking and vaping dry herb cannabis. This study will also examine the differences in toxicant exposure and cardiovascular disease risk between smoking cannabis and smoking tobacco cigarettes.
San Francisco, California and other locations
Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures
Sorry, not yet accepting patients
This is an unblinded pilot study of an environmental exposure to secondhand cannabis smoke in one group of healthy nonsmokers.
San Francisco, California
Social Media Intervention to Stop Nicotine and Cannabis Vaping Among Adolescents
Sorry, in progress, not accepting new patients
Social media based intervention to support teens in their efforts to quit vaping.
San Francisco, California
MARY-JANE Cannabis and Heart Rhythm Trial
Sorry, not yet accepting patients
Despite recreational cannabis now being legal in 23 states, where more than 100 million Americans reside, studies on the actual health effects are limited. This study is a randomized trial, where each participant will be instructed to consume or avoid cannabis on randomly assigned days during a 14-day monitoring period. The goal of this study is to answer the question: "Does cannabis use increase the frequency of 'early' and abnormal heart beats?" During the 14-day period, participants will wear an external heart monitor, a glucose monitor, and a fitness tracker to track heart rhythm, glucose levels, step counts, and sleep health. Participants will use a mobile app or a text messaging service for daily instructions/reminders on cannabis use, and short surveys. The investigators ask that participants smoke or vape cannabis at least once on days they are instructed to consume cannabis. Compelling evidence of heart and other health effects would be important to the clinical care of our patients.
San Francisco, California and other locations
Clinical Pharmacology of Marijuana-Tobacco Co-administration
Sorry, not yet accepting patients
This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.
San Francisco, California
Our lead scientists for Cannabis research studies include Gideon St. Helen, PhD Suzaynn F Schick Pamela Ling, MD Ellen Herbst, MD Gregory M Marcus, MD, MAS.
Last updated: